Arcturus Therapeutics Holdings' (ARCT) CEO Joseph Payne on Q1 2021 Results - Earnings Call Transcript

Arcturus Therapeutics Holdings, Inc. (NASDAQ:ARCT) Q1 2021 Earnings Conference Call May 10, 2021 4:30 PM ET

Company Participants

Neda Safarzadeh – Head of Investor Relations, Public Relations and Marketing
Joseph Payne – President and Chief Executive Officer
Andy Sassine – Chief Financial Officer
Steve Hughes – Chief Medical Officer

Conference Call Participants

Yasmeen Rahimi – Piper Sandler
Yigal Nochomovitz – Citigroup
Wangzhi Li – Ladenburg
Shubhendu Sen Roy – Brookline
Steven Seedhouse – Raymond James
Yale Jen – Laidlaw & Company

Operator

Greetings, and welcome to the Arcturus Therapeutics First Quarter Conference Call. During the presentation, all participants will be in a listen-only mode. Afterwards we will conduct a question-and-answer session. [Operator Instructions] As a reminder, this conference is being recorded today, Monday, May 10, 2021.

And I’d like to turn the conference over to Neda Safarzadeh, Head of Investor Relations, Public Relations and Marketing of Arcturus. Please go ahead.

Neda Safarzadeh

Thank you, operator, and good afternoon, everyone. We are joined today by Joseph Payne, President and CEO; Andy Sassine, CFO; Dr. Pad Chivukula, CSO and COO; Dr. Steve Hughes, our Chief Medical Officer.

Before we begin, I would like to remind everyone that except for statements of historical facts, the statements made by management and any responses to questions on this conference call constitute forward-looking statements that involve substantial risks and uncertainties for purposes of the Safe Harbor provided by the Private Securities Litigation Reform Act of 1995.

Any statements other than the statements of historical facts included in this communication, including those regarding the status and results of clinical development programs, the planned initiation, design or completion of clinical trials, the likelihood of success of the company's coronavirus COVID-19 vaccine candidate or other product candidates, the company’s future manufacturing and other operations, and the company's current and future cash and financial position are